Jafron Biomedical Co Ltd (300529) — Cash Flow-to-Debt Ratio
Jafron Biomedical Co Ltd (300529) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of CN¥35.34 Million could theoretically repay 0% of its total liabilities (CN¥2.11 Billion) in one year. Explore 300529 long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jafron Biomedical Co Ltd Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Jafron Biomedical Co Ltd across 15 annual periods. Also explore 300529 asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Jafron Biomedical Co Ltd (2011–2025)
Year-by-year debt coverage analysis for Jafron Biomedical Co Ltd. For market capitalisation and broader financial context, see 300529 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | CN¥721.22 Million | CN¥1.94 Billion | ▼ -27.4% |
| 2024 | 0.51x | CN¥1.05 Billion | CN¥2.05 Billion | ▲ +33.8% |
| 2023 | 0.38x | CN¥916.74 Million | CN¥2.39 Billion | ▼ -20.9% |
| 2022 | 0.48x | CN¥883.80 Million | CN¥1.82 Billion | ▼ -44.6% |
| 2021 | 0.88x | CN¥1.25 Billion | CN¥1.43 Billion | ▼ -65.0% |
| 2020 | 2.50x | CN¥957.49 Million | CN¥383.06 Million | ▲ +38.8% |
| 2019 | 1.80x | CN¥583.50 Million | CN¥324.13 Million | ▲ +54.7% |
| 2018 | 1.16x | CN¥384.08 Million | CN¥330.04 Million | ▲ +19.0% |
| 2017 | 0.98x | CN¥304.10 Million | CN¥310.90 Million | ▼ -36.6% |
| 2016 | 1.54x | CN¥178.64 Million | CN¥115.81 Million | ▼ -6.3% |
| 2015 | 1.65x | CN¥205.18 Million | CN¥124.61 Million | ▲ +3.8% |
| 2014 | 1.59x | CN¥137.35 Million | CN¥86.59 Million | ▼ -2.9% |
| 2013 | 1.63x | CN¥133.33 Million | CN¥81.60 Million | ▼ -31.1% |
| 2012 | 2.37x | CN¥120.25 Million | CN¥50.74 Million | ▼ -5.7% |
| 2011 | 2.51x | CN¥77.06 Million | CN¥30.68 Million | — |